Abstract:Background: Conversion therapy provides selected patients with unresectable hepatocellular carcinoma the opportunity to undergo a curative hepatectomy and achieve long-term survival. Although various regimens have been used for conversion therapy, their conversion rate and safety remain uncertain. Therefore, we conducted some meta-analyses to evaluate the efficacy and safety of several conversion regimens in order to elucidate the optimal regimen. Method: We performed systematic literature research on PubMed, Embase, and the Web of Science until July 30, 2022. Chemotherapy, transcatheter arterial chemoembolization (TACE), molecular therapy (targeted therapy, immunotherapy, or a combination of both), and combined locoregional-systemic therapy were the conversion regimens we targeted. Results: Twenty-four studies were included. The pooled conversion rates for chemotherapy, TACE, molecular therapy, and combined locoregional-systemic therapy were 13% (95% confidence interval [CI], 7%–20%; I2 = 82%), 12% (95% CI, 9%–15%; I2 = 60%), 10% (95% CI, 3%–20%; I2 = 90%), and 25% (95% CI, 13%–38%; I2 = 89%), respectively. The pooled objective response rates (ORR) for chemotherapy, TACE, molecular therapy, and combined locoregional-systemic therapy were 19% (95% CI, 12%–28%; I2 = 77%), 32% (95% CI, 15%–51%; I2 = 88%), 30% (95% CI, 15%–46%; I2 = 93%), and 60% (95% CI, 41%–77%; I2 = 91%), respectively. The pooled grade ≥3 AEs for chemotherapy, TACE, molecular therapy, and combined locoregional-systemic therapy were 67% (95% CI, 55%–78%; I2 = 79%), 34% (95% CI, 8%–66%; I2= 92%), 30% (95% CI, 18%–43%; I2 = 84%), and 40% (95% CI, 23%–58%; I2 = 89%), respectively. Subgroup analyses showed the conversion rate, ORR and grade ≥3 AE rate for tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor (ICI) and locoregional therapy (LRT) were 33% (95% CI, 17%-52%; I2 = 89%), 73% (95% CI, 51%–91%; I2 = 90%), 31% (95% CI, 10%-57%; I2 = 89%), respectively. Conclusion: Combined locoregional-systemic therapy, especially TKI combined with ICI and LRT, may be the most effective conversion therapy regimen, associated with a significant ORR, conversion potential, and an acceptable safety profile.

Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma

Sorafenib In Advanced Hepatocellular Carcinoma: Current Status And Future Perspectives

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma

ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma

Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis

Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis

Long-term Disease-Free Survival Achieved by Anti-Angiogenic Therapy Plus Surgery in a Hepatocellular Carcinoma Patient with Extensive Liver Involvement and Lung Metastases.

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

Conversion of Initially Unresectable Hepatocellular Carcinoma (HCC) with Triple-Combination Therapy (lenvatinib, Anti-Pd-1 Antibodies, and Transarterial Therapy): A Retrospective Analysis

Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients

Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

Sorafenib Versus Transarterial Chemoembolization As Adjuvant Therapies for Patients with Hepatocellular Carcinoma and Microvascular Invasion.

A glycopeptide extract can inhibit cytotoxic T lymphocyte-target cell conjugation in an H-2-restricted manner.

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

Therapeutic Efficacy and Prognostic Factors of Sorafenib Treatment in Patients with Unresectable Primary Hepatocellular Carcinoma

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review

Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma

Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis